| Literature DB >> 17386104 |
Julian Mettler1, Mathew Simcock, Pedram Sendi, Andreas F Widmer, Roland Bingisser, Manuel Battegay, Ursula Fluckiger, Stefano Bassetti.
Abstract
BACKGROUND: Several strategies to optimise the use of antibiotics have been developed. Most of these interventions can be classified as educational or restrictive. Restrictive measures are considered to be more effective, but the enforcement of these measures may be difficult and lead to conflicts with prescribers. Any intervention should be aimed at targets with the highest impact on antibiotic prescribing. The aim of the present study was to assess the adequacy of empirical and adjusted antibiotic therapies in a Swiss university hospital where no antibiotic use restrictions are enforced, and to identify risk factors for inadequate treatment and targets for intervention.Entities:
Mesh:
Substances:
Year: 2007 PMID: 17386104 PMCID: PMC1847433 DOI: 10.1186/1471-2334-7-21
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Characteristics of the 539 included patients.
| Characteristic | Number of patients (n = 539) | Percentage of all patients |
| Males | 297 | 55.1% |
| Age in years (median; range) | 69 [17–100] | |
| 17 to 40 years | 96 | 17.8% |
| 41 to 60 years | 104 | 19.3% |
| More than 60 years | 339 | 62.9% |
| Ward a | ||
| Medicine and geriatrics | 359 | 66.6% |
| Surgery | 173 | 32.1% |
| Medical intensive care | 25 | 4.6% |
| Surgical intensive care | 10 | 1.9% |
| Neurology | 4 | 0.7% |
| Main infectious disease diagnosis upon admission | ||
| Respiratory tract infections | 169 | 31.4% |
| Urinary tract infections, prostatitis, epididimytis | 113 | 21.0% |
| Gastrointestinal infections b | 81 | 15.0% |
| Skin and soft tissue infections | 42 | 7.8% |
| Biliary tract infections | 25 | 4.6% |
| Suspected systemic infections without identified focus c | 25 | 4.6% |
| Sepsis d | 22 | 4.1% |
| Bone and joint infections | 17 | 3.2% |
| Ear, nose and throat infections | 15 | 2.8% |
| Central nervous system infections | 11 | 2.0% |
| Neutropenic fever | 10 | 1.9% |
| Other | 5 | 0.9% |
| No infectious disease diagnosis | 4 | 0.7% |
| Total number of patients with SIRS e | 256 | 47.5% |
| Charlson comorbidity index [15] (mean +/-SD) | 2.4 (+/- 2.3) | |
| McCabe index [16] - not fatal | 443 | 82.2% |
| McCabe index - fatal < 5 years | 64 | 11.9% |
| McCabe index - fatal < 6 months | 32 | 5.9% |
| Died in hospital | 31 | 5.8% |
a If patients were on more than one ward, each ward was counted separately.
b Includes gastroenteritis, diverticulitis, peritonitis, enterocolitis, appendicitis, abdominal abscess, acute abdomen.
c These patients did not meet the criteria of the sepsis definition.
d Sepsis: defined as clinical evidence of infection, plus SIRSe.
e Systemic inflammatory response syndrome (SIRS): includes two or more of the following: temperature > 38°C or < 36°C, heart rate > 90 beats per minute, leukocytes > 12,000/μL or < 4,000/μL (band forms were not routinely determined and were therefore not considered), respiratory rate > 20 per minute.
Most frequently used empirical and adjusted antibiotic therapies
| Type of therapy | Number of patients | % |
| Amoxicillin/clavulanate | 223 | 41.4% |
| Ciprofloxacin | 88 | 16.3% |
| Piperacillin/tazobactam | 55 | 10.2% |
| Amoxicillin/clavulanate + clarithromycin | 33 | 6.1% |
| Ceftriaxone | 23 | 4.3% |
| Cefepime + amikacin | 18 | 3.3% |
| Amoxicillin/clavulanate + amikacin | 12 | 2.2% |
| Ciprofloxacin + metronidazole | 9 | 1.7% |
| Trimethoprim/sulfamethoxazole | 6 | 1.1% |
| Norfloxacin | 6 | 1.1% |
| Cefepime | 5 | 0.9% |
| Ceftriaxone + clarithromycin | 5 | 0.9% |
| Other antibiotics or antibiotic combinations | 56 | 10.4% |
| Amoxicillin/clavulanate | 29 | 17.3% |
| Piperacillin/tazobactam | 22 | 13.1% |
| Ciprofloxacin | 15 | 8.9% |
| Penicillin | 12 | 7.1% |
| Amoxicillin/clavulanate + ciprofloxacin | 8 | 4.8% |
| Amoxicillin/clavulanate + clarithromycin | 6 | 3.6% |
| Meropenem | 5 | 3.0% |
| Cefuroxime | 5 | 3.0% |
| Other antibiotics or antibiotic combinations a | 66 | 39.3% |
a e.g.: ceftriaxone (4 patients), flucloxacillin (3), amoxicillin (3), levofloxacin (3), ciprofloxacin + metronidazole (3), ciprofloxacin + rifampicin (2), cefepime (2), cefepime + tobramycin (2), clindamycin (2), trimethoprim/sulfamethoxazole (2), imipenem/cilastatin (2), vancomycin (2), ceftriaxone + rifampicin (2), cefuroxime + clarithromycin (2).
Reasons for inadequacy of empirical and adjusted antibiotic therapies
| Reason for inadequacy a | Number of patients | % |
| Inadequate empirical therapy | 121 | 100% |
| Spectrum too broad | 29 | 24.0% |
| Inadequate duration | 28 | 23.1% |
| Insufficient dosage | 27 | 22.3% |
| Spectrum too narrow | 22 | 18.2% |
| Wrong spectrum/inadequate use b | 21 | 17.4% |
| Excessive dosage | 3 | 2.5% |
| Inadequate adjusted therapy | 46 | 100% |
| Spectrum too broad | 24 | 52.2% |
| Wrong spectrum/inadequate use c | 12 | 26.1% |
| Insufficient dosage | 7 | 15.2% |
| Inadequate duration | 2 | 4.4% |
| Excessive dosage | 1 | 2.2% |
| Spectrum too narrow | 1 | 2.2% |
a More than one reason may apply for each patient.
b If antibiotic given covered completely different spectrum than expected bacteria would require or no antibiotic therapy was warranted.
c If bacteriological results had shown that identified bacteria were resistant to antibiotics used, or antibiotic covered completely different spectrum than expected bacteria would require or no antibiotic therapy was warranted.
Characteristics of patients receiving adequate or inadequate empirical antibiotic treatment (univariate analysis).
| Characteristic | Patients (n) receiving adequate empirical antibiotic treatment | Patients (n) receiving inadequate empirical antibiotic treatment | p-value | OR (95% CI) for adequate therapy |
| Number of patients | 418 (77.6%) | 121 (22.4%) | ||
| Women | 170 (70.2%) | 72 (29.8%) | ||
| Median age and range (years) | 67 [18–100] | 72 [17–97] | ||
| < 40 years | 74 (77.1%) | 22 (22.9%) | 0.904 | 0.97 (0.57–1.64) |
| 41 – 60 yr. | 91 (87.5%) | 13 (12.5%) | ||
| > 60 years | 253 (74.6%) | 86 (25.4%) | ||
| Medicine/Geriatrics | 281 (78.3%) | 78 (21.7%) | 0.399 | 1.19 (0.80–1.76) |
| Surgery | 135 (78.9%) | 36 (21.1%) | 0.733 | 1.09 (0.70–1.65) |
| Medical and surgical intensive care | 25 (71.4%) | 10 (28.6%) | 0.408 | 0.73 (0.34–1.55) |
| Neurology | 1 (25.0%) | 3 (75.0%) | ||
| 25 (80.6%) | 6 (19.4%) | 0.671 | 1.22 (0.49–3.04) | |
| Charlson index total 0 | 110 (81.5%) | 25 (18.5%) | 0.206 | 1.37 (0.84–2.24) |
| Charlson index total 1 – 5 | 264 (75.9%) | 84 (24.1%) | 0.205 | 0.76 (0.49–1.17) |
| Charlson index total > 5 | 44 (78.6%) | 12 (21.4%) | 0.845 | 1.07 (0.55–2.10) |
| Not fatal | 343 (77.4%) | 100 (22.6%) | 0.882 | 0.96 (0.56–1.64) |
| Fatal (< 5 years) | 52 (81.3%) | 12 (18.8%) | 0.450 | 1.29 (0.67–2.51) |
| Fatal (< 6 months) | 23 (71.9%) | 9 (28.1%) | 0.428 | 0.73 (0.33–1.61) |
| None | 78 (77.2%) | 23 (22.8%) | 0.931 | 0.98 (0.58–1.64) |
| One or more | 340 (77.6%) | 98 (22.4%) | 0.931 | 1.02 (0.61–1.71) |
| Within 24 hours | 23 (62.2%) | 14 (37.8%) | ||
| Were involved | 58 (69.0%) | 26 (31.0%) | ||
| 128 (76.2%) | 40 (23.8%) | 0.611 | 0.89 (0.58–1.38) | |
| 1 (50.0%) | 1 (50.0%) | 0.399† | 0.29 (0.02–4.64) | |
| 100 (69.0%) | 45 (31.0%) | |||
| 62 (65.3%) | 33 (34.7%) | |||
| 29 (70.1%) | 12 (29.9%) | 0.276 | 0.68 (0.33–1.37) | |
| Biliary tract infections | 19 (76.0%) | 6 (24%) | 0.849 | 0.91 (0.36–2.34) |
| Bone and joint infections | 12 (70.6%) | 5 (29.4%) | 0.553† | 0.69 (0.24–1.99) |
| Central nervous system infections | 9 (81.8%) | 2 (18.1%) | 1.000† | 1.31 (0.28–6.14) |
| Ear, nose and throat infections | 11 (73.3%) | 4 (26.7%) | 0.753† | 0.79 (0.25–2.53) |
| Gastrointestinal infections | 59 (73.8%) | 21 (26.3%) | 0.377 | 0.78 (0.45–1.35) |
| Neutropenic fever | 10 (100%) | 0 (0.00%) | 0.127† | N/A |
| No infectious disease | 1 (25.0%) | 3 (75.0%) | ||
| Respiratory tract infections | 139 (82.2%) | 30 (17.8%) | 0.077 | 1.51 (0.95–2.39) |
| Sepsis | 19 (86.4%) | 3 (13.6%) | 0.436† | 1.87 (0.55–6.44) |
| Skin and soft tissue infections | 48 (81.4%) | 11 (18.6%) | 0.458 | 1.30 (0.65–2.58) |
| Suspected systemic infections without identified focus | 19 (76.0%) | 6 (24.0%) | 0.849 | 0.91 (0.36–2.34) |
| Urinary tract infections, prostatitis, epididimytis | 83 (73.5%) | 30 (26.6%) | 0.240 | 0.75 (0.47–1.21) |
| Other | 11 (68.8%) | 5 (31.3%) | 0.371† | 1.30 (0.21–1.84) |
| 199 (77.7%) | 57 (22.3%) | 0.923 | 1.02 (0.68–1.53) |
Note: The adequacy of treatment was compared against the individual variables with the Chi-squared test with odds ratio production
* Wilcoxon-Mann-Whitney test
† Fisher's Exact test
Characteristics of patients receiving adequate or inadequate adjusted antibiotic treatment (univariate analysis)
| Characteristic | Patients (n) receiving adequate adjusted antibiotic treatment | Patients (n) receiving inadequate adjusted antibiotic treatment | p-value | OR (95% CI) for adequate therapy |
| Number of patients | 121 (72.5%) | 46 (27.5%) | ||
| Women | 54 (70.1%) | 23 (29.9%) | 0.534 | 0.81 (0.41–1.59) |
| Median age and range (years) | 65 [21–97] | 70 [19–95] | 0.115* | |
| < 40 | 22 (78.6%) | 6 (21.4%) | 0.427 | 1.48 (0.56–3.93) |
| 41 – 60 | 29 (80.6%) | 7 (19.4%) | 0.219 | 1.76 (0.71–4.35) |
| > 60 | 70 (68.0%) | 33 (32.0%) | 0.099 | 0.54 (0.26–1.13) |
| Medicine/Geriatrics | 85 (72.0%) | 33 (28.0%) | 0.472 | 0.77 (0.38–1.56) |
| Surgery | 36 (73.5%) | 13 (26.5%) | 0.955 | 0.98 (0.47–2.06) |
| Medical and surgical intensive care | 13 (86.7%) | 2 (13.3%) | 0.360† | 2.45 (0.53–11.28) |
| Neurology | 0 (0.0%) | 0 (0.0%) | N/A | N/A |
| 10 (90.9%) | 1 (9.1%) | 0.293† | 4.05 (0.50–32.60) | |
| Switch due to bacterial lab results | 58 (89.2%) | 7 (10.7%) | ||
| Switch due to other reason | 43 (64.2%) | 24 (35.8%) | 0.050 | 0.51 (0.25–1.01) |
| Charlson index total 0 | 26 (76.5%) | 8 (23.5%) | 0.557 | 1.30 (0.54–3.13) |
| Charlson index total 1 – 5 | 84 (71.8%) | 33 (28.2%) | 0.770 | 0.89 (0.42–1.89) |
| Charlson index total > 5 | 11 (68.8%) | 5 (31.2%) | 0.771† | 0.82 (0.27–2.50) |
| Not fatal | 97 (74.0%) | 34 (26.0%) | 0.380 | 1.43 (0.64–3.16) |
| Fatal (< 5 years) | 18 (75.0%) | 6 (25.0%) | 0.763 | 1.17 (0.43–3.15) |
| Fatal (< 6 months) | 6 (50.0%) | 6 (50.0%) | 0.055† | 0.35 (0.11–1.14) |
| None | 13 (76.5%) | 4 (23.5%) | 0.783† | 1.26 (0.39–4.10) |
| One or more | 108 (72%) | 42 (28%) | 0.783† | 0.79 (0.24–2.57) |
| Within 24 hours | 22 (88.0%) | 3 (12.0%) | 0.059 | 3.19 (0.91–11.21) |
| Were involved | 52 (82.5%) | 11 (17.5%) | ||
| 1 (100.0%) | 0 (0.0%) | 1.000† | N/A | |
| 34 (70.8%) | 14 (29.2%) | 0.766 | 0.89 (0.43–1.88) | |
| 37 (84.1%) | 7 (15.9%) | 0.520 | 1.28 (0.60–2.72) | |
| 9 (64.3%) | 5 (35.7%) | 0.534† | 0.66 (0.21–2.08) | |
| Biliary tract infections | 5 (83.3%) | 1 (16.7%) | 1.000† | 1.94 (0.22–17.06) |
| Bone and joint infections | 10 (100.0%) | 0 (0.0%) | 0.063† | N/A |
| CNS infections | 3 (100.0%) | 0 (0.0%) | 0.562† | N/A |
| Ear, nose and throat infections | 0 (0.00%) | 1 (100%) | 0.275† | N/A |
| Gastrointestinal infections | 17 (63.0%) | 10 (37.0%) | 0.228 | 0.59 (0.25–1.40) |
| Urinary tract infections, postatitis, epididimytis | 21 (67.7%) | 10 (32.3%) | 0.52 | 0.76 (0.33–1.76) |
| Neutropenic fever | 6 (85.7%) | 1 (14.3%) | 0.675† | 2.35 (0.28–20.05) |
| Respiratory tract infections | 34 (60.7%) | 22 (39.3%) | ||
| Sepsis | 12 (92.3%) | 1 (7.7%) | 0.116† | 4.95 (0.63–39.24) |
| Skin and soft tissue infections | 10 (71.4%) | 4 (28.6%) | 1.000† | 0.95 (0.28–3.18) |
| Suspected systemic infections without identified focus | 5 (71.4%) | 2 (28.6%) | 1.000† | 0.95 (0.18–5.07) |
| Other | 8 (88.9%) | 1 (11.1%) | 0.447† | 3.19 (0.39–26.21) |
* Wilcoxon-Mann-Whitney test
† Fisher's Exact test